The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Psoriasis Pathogenesis and Treatment
Open accessAbstract
Research on psoriasis pathogenesis has largely increased knowledge on skin biology in general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of psoriasis have been translated into targeted and highly effective therapies providing fundamental insights into the pathogenesis of chronic inflammatory diseases with a dominant IL-23/Th17 axis. This review discusses the mechanisms involved in the initiation and development of the disease, as well as the therapeutic options that have arisen from the dissection of the inflammatory psoriatic pathways. Our discussion begins by addressing the inflammatory pathways and key cell types initiating and perpetuating psoriatic inflammation. Next, we describe the role of genetics, associated epigenetic mechanisms, and the interaction of the skin flora in the pathophysiology of psoriasis. Finally, we include a comprehensive review of well-established widely available therapies and novel targeted drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
The Wellcome Trust Case Control Consortium, Management Committee, Burton, P. R., Clayton, D. G., Cardon, L. R., Craddock, N., Deloukas, P., Duncanson, A., Kwiatkowski, D. P., McCarthy, M. I., et al. (2007) · Nature · doi:10.1038/nature05911 · Cited by 9,442
Byrd, A. L., Belkaid, Y., & Segre, J. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.157 · Cited by 2,806
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence
Parisi, R., Symmons, D. P. M., Griffiths, C. E. M., & Ashcroft, D. M. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.339 · Cited by 2,592
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A.-M., Florencia, E., Prens, E. P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802999 · Cited by 2,176
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997 · cited 1×
“Candida infections are more frequent in patients receiving anti-IL17 biologics secukinumab and ixekizumab compared to etanercept [209].”
BackgroundRisk of myocardial infarction in patients with psoriasis
Gelfand, J. M., Neimann, A. L., Shin, D. B., Wang, X., Margolis, D. J., & Troxel, A. B. (2006) · JAMA · doi:10.1001/jama.296.14.1735 · Cited by 1,899
Psoriasis causes as much disability as other major medical diseases
Rapp, S. R., Feldman, S. R., Exum, M. L., Fleischer, A. B., & Reboussin, D. M. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70112-x · Cited by 1,491
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
for the Collaborative Association Study of Psoriasis, Nair, R. P., Duffin, K. C., Helms, C., Ding, J., Stuart, P. E., Goldgar, D., Gudjonsson, J. E., Li, Y., Tejasvi, T., et al. (2009) · Nature Genetics · doi:10.1038/ng.311 · Cited by 1,409
Cited by
Jang, D.-I., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., & Yang, S.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052719 · Cited by 1,694
Advances in the pathogenesis of psoriasis: from keratinocyte perspective
Zhou, X., Chen, Y., Cui, L., Shi, Y., & Guo, C. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04523-3 · Cited by 632
Pathological angiogenesis: mechanisms and therapeutic strategies
Dudley, A. C., & Griffioen, A. W. (2023) · Angiogenesis · doi:10.1007/s10456-023-09876-7 · Cited by 495
Mäder, P., & Kattner, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00960 · Cited by 438
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
The Prevalence of Autoimmune Disorders in Women: A Narrative Review
Angum, F., Khan, T., Kaler, J., Siddiqui, L., & Hussain, A. (2020) · Cureus · doi:10.7759/cureus.8094 · Cited by 397
The Immunology of Psoriasis-Current Concepts in Pathogenesis
Sieminska, I., Pieniawska, M., & Grzywa, T. M. (2024) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-024-08991-7 · Cited by 346
New Treatment Addressing the Pathogenesis of Psoriasis
Tokuyama, M., & Mabuchi, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207488 · Cited by 291
Liu, J., Liu, Z., Pang, Y., & Zhou, H. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01343-7 · Cited by 219
The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications
Singh, R., Koppu, S., Perche, P. O., & Feldman, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312793 · Cited by 192
Current Concepts of Psoriasis Immunopathogenesis
Vičić, M., Kaštelan, M., Brajac, I., Sotošek, V., & Massari, L. P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111574 · Cited by 163
Deep Learning Application for Effective Classification of Different Types of Psoriasis
Aijaz, S. F., Khan, S. J., Azim, F., Shakeel, C. S., & Hassan, U. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/7541583 · Cited by 77
“Normally, a skin cell develops over a period of 28 to 30 days;, however, in case of psoriasis, this cycle is disturbed and accelerated leading to development of skin cells on the skin surface in 7 days [4].”
BackgroundExperimental Pharmacological Management of Psoriasis
Campione, E., Cosio, T., Di Prete, M., Lanna, C., Dattola, A., & Bianchi, L. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s265632 · Cited by 27
The Role of RhoH in TCR Signalling and Its Involvement in Diseases
Ahmad Mokhtar, A. M., Hashim, I. F., Mohd Zaini Makhtar, M., Salikin, N. H., & Amin-Nordin, S. (2021) · Cells · doi:10.3390/cells10040950 · Cited by 25
Quantification of Immunohistochemically Stained Cells in Skin Biopsies
Emmanuel, T., Brent, M. B., Iversen, L., & Johansen, C. (2022) · Dermatopathology · doi:10.3390/dermatopathology9020011 · Cited by 10
Liu, H., Wang, K., Yang, L., Zhou, Y., Li, Y., Tang, E., Li, D., Gan, Y., Zhou, C., Wang, L., et al. (2025) · International Journal of Biometeorology · doi:10.1007/s00484-024-02847-7 · Cited by 2
Metadata
- Authors
- Rendon, A., & Schäkel, K.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-03-23
- Volume
- 20
- Issue
- 6
- Pages
- 1475
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2924895007
- Cited by
- 2,064
- References
- 181
- FWCI
- 54.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.